OF SHARED RESOURCE Since the founding of the Sidney Kimmel Comprehensive Cancer Center (SKCCC) Analytical Pharmacology Core (APC) in 1985, the primary mission of the APC has been to enable the inclusion of critical pharmacological endpoints in the design of clinical trials and preclinical studies, and stimulate new hypotheses and areas of investigation by providing by-cost, state-of-the-art services. The APC provides state-of-the-art equipment and facilities in 1200 square feet of laboratory space on the first floor of the SKCCC Cancer Research Building (CRBI). The location of the APC is adequate to meet the needs of the SKCCC investigators to investigate the pharmacokientics, pharmacodynamics, and pharmacogenetics of anticancer agents. Services include pharmacological trial design, analytical method development and validation, pharmacokinetic and pharmacodynamic data analysis and interpretation, and consultation for design of in vitro drug metabolism, protein binding studies, non-invasive phenotypic probes for drug metabolizing enzymes, and pharmacogenetic studies. The APC houses five UPLC/HPLC instruments with a UV/fluorescence (1), triple stage quadruple mass spectrometer (3), and a QTrap system with ion trap capabilities (1) for more intricate drug metabolism studies. The APC sample analysis has steadily increased since 2005 and is analyzing more than 4,000 samples/year with 20 new methods developed/year, serving over 26 faculty members who are members of eleven CCSG Programs with the majority of the users having peer-reviewed funding. The requested CCSG funding will support personnel who provide consultative services related to assay development, protocol design, and data interpretation, and who ensure that instrumentation is suitably maintained and available for investigators seeking support from the APC Lay: The ability to quantify drugs and their metabolites in cells, plasma, and tissues is an essential need in research aimed at determining how drugs go through the body and the link to the drug's effects both in animals and in humans. The Analytical Pharmacology Core laboratory provides services to design, conduct, and interpret this data. SKCCC Managed Shared Resource Current Grant Year Reporting Period: January 1, 2010 to December 31, 2010

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA006973-49
Application #
8559534
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-05-07
Project End
2017-04-30
Budget Start
2012-08-09
Budget End
2013-04-30
Support Year
49
Fiscal Year
2012
Total Cost
$182,687
Indirect Cost
$69,917
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Woodard, Lauren E; Dennis, Cindi L; Borchers, Julie A et al. (2018) Nanoparticle architecture preserves magnetic properties during coating to enable robust multi-modal functionality. Sci Rep 8:12706
Shrestha, Eva; White, James R; Yu, Shu-Han et al. (2018) Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer. J Urol 199:161-171
Gordy, James T; Luo, Kun; Francica, Brian et al. (2018) Anti-IL-10-mediated Enhancement of Antitumor Efficacy of a Dendritic Cell-targeting MIP3?-gp100 Vaccine in the B16F10 Mouse Melanoma Model Is Dependent on Type I Interferons. J Immunother 41:181-189
El-Diwany, Ramy; Soliman, Mary; Sugawara, Sho et al. (2018) CMPK2 and BCL-G are associated with type 1 interferon-induced HIV restriction in humans. Sci Adv 4:eaat0843
Kyker-Snowman, Kelly; Erlanger Avigdor, Bracha; Nasim, Mansoor et al. (2018) A primary breast cancer with distinct foci of estrogen receptor-alpha positive and negative cells derived from the same clonal origin as revealed by whole exome sequencing. Breast Cancer Res Treat 170:425-430
Christenson, Eric S; Antonarakis, Emmanuel S (2018) PARP inhibitors for homologous recombination-deficient prostate cancer. Expert Opin Emerg Drugs 23:123-133
Ambinder, Richard F (2018) A viral protein kinase drug target for tumors? J Clin Invest 128:2197-2198
Lee, Alice J; Montgomery, Madeline C; Patel, Rupa R et al. (2018) Improving Insurance and Health Care Systems to Ensure Better Access to Sexually Transmitted Disease Testing and Prevention. Sex Transm Dis 45:283-286
Bharathy, Narendra; Berlow, Noah E; Wang, Eric et al. (2018) The HDAC3-SMARCA4-miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma. Sci Signal 11:
McGrath-Morrow, Sharon A; Ndeh, Roland; Helmin, Kathryn A et al. (2018) DNA methylation regulates the neonatal CD4+ T-cell response to pneumonia in mice. J Biol Chem 293:11772-11783

Showing the most recent 10 out of 2393 publications